NNFN Stock Overview
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MannKind Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.86 |
| 52 Week High | US$4.96 |
| 52 Week Low | US$2.97 |
| Beta | 1.32 |
| 1 Month Change | -14.27% |
| 3 Month Change | 23.34% |
| 1 Year Change | 8.98% |
| 3 Year Change | -4.13% |
| 5 Year Change | 187.70% |
| Change since IPO | -92.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| NNFN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -1.2% | 1.7% |
| 1Y | 9.0% | -23.0% | 2.3% |
Price Volatility
| NNFN volatility | |
|---|---|
| NNFN Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NNFN has not had significant price volatility in the past 3 months.
Volatility Over Time: NNFN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 413 | Michael Castagna | www.mannkindcorp.com |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company’s product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
MannKind Corporation Fundamentals Summary
| NNFN fundamental statistics | |
|---|---|
| Market cap | €1.05b |
| Earnings (TTM) | -€11.15m |
| Revenue (TTM) | €185.91m |
5.7x
P/S Ratio-95.0x
P/E RatioIs NNFN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NNFN income statement (TTM) | |
|---|---|
| Revenue | US$198.96m |
| Cost of Revenue | US$62.77m |
| Gross Profit | US$136.19m |
| Other Expenses | US$148.13m |
| Earnings | -US$11.94m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.044 |
| Gross Margin | 68.45% |
| Net Profit Margin | -6.00% |
| Debt/Equity Ratio | -109.2% |
How did NNFN perform over the long term?
See historical performance and comparison